Key result
Patient sex shows no association with platelet aggregation during triple antiplatelet therapy for MI.
Why the study?
Are there sex differences in platelet reactivity in patients with myocardial infarction treated with triple antiplatelet therapy?
Are there sex differences in platelet reactivity in patients with myocardial infarction treated with triple antiplatelet therapy?
The study found no sex differences in platelet aggregation among MI patients on triple antiplatelet therapy, suggesting that excess dosing does not explain the increased bleeding risk in women.
Does not support excess dosing as cause of women's higher bleeding risk on triple therapy post-MI; leaves open alternative mechanisms for prospective study.
-selectin. The main finding of this study was a consistent lack of difference between the sexes in platelet aggregation, using three different agonists at several time-points. Our results do not support excess dosing of anti-platelet drugs as a major explanation for increased bleeding risk in women.
No takes yet. Share an insight, caveat, or question.
Holm et al. (2020) studied this question. Patient sex was not associated with differences in platelet aggregation during triple antiplatelet therapy for myocardial infarction, indicating excess dosing does not explain women's bleeding risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: